BRUSSELS Aug 27 Belgian biotech firm Ablynx burnt through more cash in the first half of 2015, as it increased spending on research and clinical trials for its experimental drugs.
The group, which makes treatments based on nanobodies, small antibodies found in llamas and alpacas, said it used up 35 million euros ($39.7 million) of cash in the first half of 2015.
09:59 Spanish banks up provisions as mortgage floor hit tops 3 bln euros19
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High11
21:52 Netflix nears 94 million subscribers 10 years after streaming launch20
22:33 Allergan to pay $15 million over failing to disclose merger talks19